Sunday, March 07, 2021 8:50:23 AM
TAZ
Per Year REVENUE ESTIMATE without COVID CLEAR Business
$25,920,000.00 annual gross estimate at 90%
25% net income (based on newer industry, high demand high income standard)
$6,480,000.00 net income annual income
OS 2,105,849,131 = Income per share .003
PE 25 = Price of .076 per share
Note: CEO Goal is 1000 beds (at 26 seconds of video)
https://americanbusinesstelevisionnetwork.vhx.tv/stocks-fast-movers/videos/ethema-health-corporation-otcqb-grst
At 1000 beds, valuation = around .64 per share. Holding 2.0 million shares for 5 years your $7,200 becomes $1,200,000.00
GRST Aria HAS RECEIVED PROVIDER NUMBER FROM BLUE CROSS and Many Others =$$$$
1st Facility Up and Running!
West Palm Beach, FL, Jan. 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Ethema Health Corporation (OTCPINK: GRST) (“Ethema” “GRST” or the “Company”) is pleased to announce that the audit for the full licensing of the ARIA treatment facility by the Department of Children and Family Service for Florida (“DCF”) which commenced on December 10, 2020 has resulted in the issuance of a full license for all five levels of care that ARIA provides. The issuance of the full licenses for each level of care were staggered and the full licenses for the final two levels of care were received January 12, 2021
Recent GRST News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 09:45:09 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/22/2023 09:54:23 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 12/22/2023 09:04:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:55:26 PM
- Form 1-A POS - • Edgar (US Regulatory) • 10/20/2023 07:29:40 PM
- Form 1-A POS - • Edgar (US Regulatory) • 08/29/2023 07:21:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 08:37:36 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 12:43:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/11/2023 04:51:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2023 06:56:41 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM